M&A Deal Summary |
|
|---|---|
| Date | 2022-03-17 |
| Target | vivitide |
| Sector | Life Science |
| Buyer(s) | Biosynth Carbosynth |
| Sellers(s) | Ampersand Capital Partners |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Biosynth Carbosynth is a fully hybrid research products, life sciences reagents and custom synthesis and manufacturing services company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, phospholipids, enzyme substrates, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Biosynth Carbosynth was formed in 1965 and is based in St. Gallen, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 7 |
| Sector (Life Science) | 1 of 6 |
| Type (Add-on Acquisition) | 1 of 7 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2022) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-26 |
Aalto Bio Reagents
Dublin, Ireland Aalto Bio Reagents is a developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in emerging diseases. Aalto Bio Reagents was founded in 1978 and is based in Dublin, Ireland. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 51 of 53 |
| Sector (Life Science) | 23 of 24 |
| Type (Add-on Acquisition) | 37 of 38 |
| State (Massachusetts) | 14 of 14 |
| Country (United States) | 49 of 50 |
| Year (2022) | 4 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-03-01 |
BioEcho Life Sciences
Koln, Germany BioEcho Life Sciences specializes in nucleic acid sample preparation tools for clinical, biotech, life sciences research, agricultural, and industrial applications. BioEcho was established with the mission of utilizing the company’s proprietary technologies and technical expertise to overcome the limitations of many standardized methods in molecular biology and diagnostic workflows. The company's kits offer customers industry-leading quality, speed, simplicity, and sustainability capabilities for the purification of high-quality nucleic acids from a wide variety of samples. BioEcho Life Sciences was formed in 2016 and is based in Koln, Germany. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-04-18 |
Syft
Christchurch , New Zealand Syft develops SIFT-MS, a form of direct mass spectrometry that analyses volatile organic compounds (VOCs) in the air with typical detection limits at parts-per-trillion level (by volume; pptv). Syft was founded in 2002 and is based in Christchurch, New Zealand. |
Buy | - |
